Home page

Preparation of ADC Payload Monoclonal Antibodies

ADCs are multi-domain molecules composed of a monoclonal antibody (mAb), a linker, and a small-molecule cytotoxin. As the number of ADCs continues to grow, the clinical immunogenicity risk associated with these agents has increasingly drawn significant attention from the industry. The design and development of neutralizing antibody assays for ADCs differ from those used for conventional antibody therapeutics and present substantial challenges.

ADC drugs are composed of a monoclonal antibody (mAb), a linker, and a small-molecule cytotoxin. ~~Multi-domain~~ Molecules. As the number of ADC drugs continues to grow, the clinical immunogenicity risk associated with ADCs is receiving increasing attention from the industry. The design and development of neutralizing antibody assays for ADCs differ from those for conventional antibody therapeutics and pose significant challenges.

Antibody applications

Monoclonal antibodies conjugated to small-molecule cytotoxins in antibody–drug conjugates (ADCs) can be used for PK profiling of ADCs and for qualitative analysis of the drug–antibody ratio (DAR), providing essential antibody reagents to accelerate ADC development.

Features and Advantages

Strong distinctiveness: Leveraging proprietary antigen–antibody preparation technologies, we have developed a monoclonal antibody against the ADC payload that exhibits high affinity, high specificity, high sensitivity, and excellent stability.

Excellent performance: As a monoclonal antibody targeting ADC‑small molecule cytotoxins, Xichang Bio has provided services to several leading domestic ADC drug companies, and its products have demonstrated strong efficacy in experimental data validation.

Comprehensive product range: including commonly used toxins and hormones such as DM1, MMAE, SN-38, Dxd, irinotecan, and budesonide, as well as customer‑customized specialized payloads.

Wide range of applications: It can identify the small-molecule moiety in antibody–drug conjugates, determine the conjugation ratio of antibodies to small-molecule toxins, and perform PK/PD blood‑sample analyses required for both animal studies and human clinical trials.

9e1d7e8793c18c7f85a9507f3de159f